[HTML][HTML] Hypoxia activated HGF expression in pancreatic stellate cells confers resistance of pancreatic cancer cells to EGFR inhibition
Background Epidermal growth factor receptor (EGFR) is an essential target for cancer
treatment. However, EGFR inhibitor erlotinib showed limited clinical benefit in pancreatic …
treatment. However, EGFR inhibitor erlotinib showed limited clinical benefit in pancreatic …
Hypoxia activated HGF expression in pancreatic stellate cells confers resistance of pancreatic cancer cells to EGFR inhibition
X Shi, M Wang, Y Zhang, X Guo, M Liu… - …, 2022 - pubmed.ncbi.nlm.nih.gov
Background Epidermal growth factor receptor (EGFR) is an essential target for cancer
treatment. However, EGFR inhibitor erlotinib showed limited clinical benefit in pancreatic …
treatment. However, EGFR inhibitor erlotinib showed limited clinical benefit in pancreatic …
Hypoxia activated HGF expression in pancreatic stellate cells confers resistance of pancreatic cancer cells to EGFR inhibition.
X Shi, M Wang, Y Zhang, X Guo, M Liu, Z Zhou… - Ebiomedicine, 2022 - europepmc.org
Background Epidermal growth factor receptor (EGFR) is an essential target for cancer
treatment. However, EGFR inhibitor erlotinib showed limited clinical benefit in pancreatic …
treatment. However, EGFR inhibitor erlotinib showed limited clinical benefit in pancreatic …
[HTML][HTML] Hypoxia activated HGF expression in pancreatic stellate cells confers resistance of pancreatic cancer cells to EGFR inhibition
X Shi, M Wang, Y Zhang, X Guo, M Liu, Z Zhou… - eBioMedicine, 2022 - ncbi.nlm.nih.gov
Background Epidermal growth factor receptor (EGFR) is an essential target for cancer
treatment. However, EGFR inhibitor erlotinib showed limited clinical benefit in pancreatic …
treatment. However, EGFR inhibitor erlotinib showed limited clinical benefit in pancreatic …
[HTML][HTML] Hypoxia activated HGF expression in pancreatic stellate cells confers resistance of pancreatic cancer cells to EGFR inhibition
X Shi, M Wang, Y Zhang, X Guo, M Liu, Z Zhou, Y Zhao… - eBioMedicine, 2022 - Elsevier
Background Epidermal growth factor receptor (EGFR) is an essential target for cancer
treatment. However, EGFR inhibitor erlotinib showed limited clinical benefit in pancreatic …
treatment. However, EGFR inhibitor erlotinib showed limited clinical benefit in pancreatic …
[引用][C] Hypoxia activated HGF expression in pancreatic stellate cells confers resistance of pancreatic cancer cells to EGFR inhibition
S Pan, M Zhou, C Zhao, T Yin, X Li, H Wang, J Yang… - 2022 - europepmc.org
Background Epidermal growth factor receptor (EGFR) is an essential target for cancer
treatment. However, EGFR inhibitor erlotinib showed limited clinical benefit in pancreatic …
treatment. However, EGFR inhibitor erlotinib showed limited clinical benefit in pancreatic …